Is Plus Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Plus Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant downgrade in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.45 and an EV to EBITDA of -0.06, which highlight its struggles in generating positive value. Comparatively, peers like Sonoma Pharmaceuticals, Inc. have a P/E ratio of -2.1124 and Petros Pharmaceuticals, Inc. at -0.1676, reinforcing the challenging environment within the industry.
The stock has underperformed significantly against the S&P 500, with a year-to-date return of -62.51% compared to the index's 12.22%, and a staggering decline of -99.02% over the past five years. This stark contrast in performance further supports the conclusion that Plus Therapeutics, Inc. is overvalued in its current state.